News
-
-
PRESS RELEASE
Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
Onco-Innovations starts process development & scale-up activities for A83B4C63, advancing towards clinical trials. Collaboration with Dalton Pharma Services to optimize production processes and ensure regulatory readiness -
-
PRESS RELEASE
Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
Onco-Innovations partners with Nanosoft Polymers for polymer process and drug formulation optimization activities. Appointment of Dave Antony as VP Corporate Finance announced -
-
PRESS RELEASE
Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
Onco-Innovations successfully scales kilogram manufacturing for ONC010 B4 precursor component, advancing nanoparticle-formulated PNKP Inhibitor Technology. Engages InvestorBrandNetwork (IBN) for market services -
-
PRESS RELEASE
Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program
Onco-Innovations Limited reports progress in scale-up and development for ONC010 oncology program, focusing on A83 and B4 precursor components. Collaboration with Dalton Pharma Services aims at future GMP production -
-
